AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 100% Upside in AVEO (AVEO): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in AVEO (AVEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes AVEO (AVEO) a Good Fit for "Trend Investing"
by Zacks Equity Research
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Wall Street Analysts Believe AVEO (AVEO) Could Rally 113%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at an 113.2% upside potential for AVEO (AVEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why
by Zacks Equity Research
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 11.11% and 2.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) Reports Q4 Loss
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of -25% and 0%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 6.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -2.13% and -2.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -30.91% and 42.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can AVEO (AVEO) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
AVEO (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -15.79% and -70.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
AVEO Collaborates with Bristol Myers to Conduct Combo Study
by Zacks Equity Research
AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.
AVEO (AVEO) Stock Jumps 89.1%: Will It Continue to Soar?
by Zacks Equity Research
AVEO (AVEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q4 Earnings Expected to Decline
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.